PMID- 15753253
OWN - NLM
STAT- MEDLINE
DCOM- 20050819
LR  - 20181113
IS  - 1071-412X (Print)
IS  - 1098-6588 (Electronic)
IS  - 1071-412X (Linking)
VI  - 12
IP  - 3
DP  - 2005 Mar
TI  - Specific inhibitory action of anisodamine against a staphylococcal superantigenic 
      toxin, toxic shock syndrome toxin 1 (TSST-1), leading to down-regulation of 
      cytokine production and blocking of TSST-1 toxicity in mice.
PG  - 399-408
AB  - Toxic shock syndrome toxin 1 (TSST-1), produced by Staphylococcus aureus 
      (including methicillin-resistant S. aureus), is a superantigenic toxin 
      responsible for toxic shock syndrome as well as neonatal TSS-like exanthematous 
      disease. TSST-1 exhibits its deleterious effects by leading to the abnormal 
      proliferation of, e.g., Vbeta2+ T cells and overproduction of proinflammatory 
      cytokines. In the present study we examined the inhibitory effect of a Chinese 
      herbal extract, anisodamine, on TSST-1 using human peripheral blood mononuclear 
      cells (PBMCs). Anisodamine inhibited the production of proinflammatory cytokines 
      better than interleukin-10 (an anti-inflammatory cytokine). The inhibitory effect 
      of anisodamine was greater than that of any tropane alkaloid examined. 
      Anisodamine acted directly on both monocytes and T cells in human PBMCs, and the 
      effect was confirmed at the transcriptional level. Inhibition of NF-kappaB 
      activation was also demonstrated. In contrast, no significant inhibition of 
      Vbeta2+ T-cell proliferation was observed. In mice injected with TSST-1, 
      anisodamine treatment significantly decreased serum proinflammatory cytokine 
      levels and prevented TSST-1-induced death. These results suggest that anisodamine 
      specifically acts against the production of cytokines (inflammatory cytokines in 
      particular) and not against Vbeta2+ T-cell proliferation and that anisodamine may 
      have a beneficial effect on TSST-1-associated disease.
FAU - Nakagawa, Saori
AU  - Nakagawa S
AD  - Division of Bacteriology, Department of Infectious Disease Control and 
      International Medicine, Niigata University Graduate School of Medical and Dental 
      Sciences, 757 Ichibanchou, Asahimachidori, Niigata 951-8510, Japan.
FAU - Kushiya, Koji
AU  - Kushiya K
FAU - Taneike, Ikue
AU  - Taneike I
FAU - Imanishi, Ken'ichi
AU  - Imanishi K
FAU - Uchiyama, Takehiko
AU  - Uchiyama T
FAU - Yamamoto, Tatsuo
AU  - Yamamoto T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Diagn Lab Immunol
JT  - Clinical and diagnostic laboratory immunology
JID - 9421292
RN  - 0 (Bacterial Toxins)
RN  - 0 (Cytokines)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Enterotoxins)
RN  - 0 (Solanaceous Alkaloids)
RN  - 0 (Superantigens)
RN  - 0 (enterotoxin F, Staphylococcal)
RN  - 01343Q8EL8 (anisodamine)
SB  - IM
MH  - Animals
MH  - Bacterial Toxins/*antagonists & inhibitors
MH  - Cell Proliferation/drug effects
MH  - Cytokines/antagonists & inhibitors/*biosynthesis
MH  - Down-Regulation/*drug effects/genetics
MH  - Drugs, Chinese Herbal/pharmacology
MH  - Enterotoxins/*antagonists & inhibitors
MH  - Humans
MH  - Leukocytes, Mononuclear/drug effects
MH  - Mice
MH  - Monocytes/drug effects
MH  - Solanaceous Alkaloids/*pharmacology
MH  - Superantigens
MH  - T-Lymphocytes/cytology/drug effects/immunology
MH  - Transcription, Genetic/drug effects
PMC - PMC1065205
EDAT- 2005/03/09 09:00
MHDA- 2005/08/20 09:00
PMCR- 2005/03/01
CRDT- 2005/03/09 09:00
PHST- 2005/03/09 09:00 [pubmed]
PHST- 2005/08/20 09:00 [medline]
PHST- 2005/03/09 09:00 [entrez]
PHST- 2005/03/01 00:00 [pmc-release]
AID - 12/3/399 [pii]
AID - 0284-04 [pii]
AID - 10.1128/CDLI.12.3.399-408.2005 [doi]
PST - ppublish
SO  - Clin Diagn Lab Immunol. 2005 Mar;12(3):399-408. doi: 
      10.1128/CDLI.12.3.399-408.2005.